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Objective: This study was performed to define the incidence of acute deep venous thrombosis (DVT) after endovascular
treatment of abdominal aortic aneurysms (AAAs). Because aortic endograft placement requires prolonged femoral vessel
instrumentation, it may be hypothesized that these patients are at increased risk for development of an acute DVT.
Patients and Methods: Fifty consecutive patients (42 men, eight women) ranging in age from 48 to 85 years (mean, 72
years) underwent endovascular treatment of an AAA from January 2000 to August 2001. Clinical examination and
bilateral lower extremity duplex ultrasonography for DVT were performed on the first postoperative day and at the
1-month follow-up visit. No patient had a prior DVT or identifiable hypercoagulable state. Seven patients (14%) had
concurrent malignant disease. Preoperative antiplatelet agents were administered in 26 patients (52%), and nine (18%)
were on warfarin sodium therapy before surgery. No new DVT prophylaxis was initiated perioperatively. Epidural
anesthesia was used in 60% of the patients, with general endotracheal anesthesia used in the remainder. Risk factors for
DVT were evaluated with univariate statistical analysis.
Results: Three patients (6%) had an acute postoperative DVT develop. Two occurred in the femoral veins, and one
occurred in the popliteal vein. Of these patients, one had been continued on perioperative anticoagulation therapy, and
the remaining two were started on low-molecular weight heparin and warfarin sodium therapy on recognition of the
DVT. One patient had an intraoperative injury of the affected common femoral vein, and this individual was the only one
to have clinical signs of a DVT. The mean follow-up period was 8 0.8 months. In this experience, factors that may have
placed patients at increased risk for an acute DVT were not identified.
Conclusion: Six percent of patients undergoing endovascular repair of AAAs had postoperative DVT develop. These
patients had a number of risk factors for the development of a DVT; however, no specific factor was identified that
predisposed to DVT. (J Vasc Surg 2002;36:912-6.)
Deep venous thrombosis (DVT) and pulmonary em-
bolism (PE) are serious complications that affect the hos-
pitalized patient. Recent investigations place the incidence
rate of DVT and PE between 69 and 139 cases per 100,000
people in the general population, with a prevalence of 350
cases per 100,000 hospital admissions.1-3 Autopsy data
suggest that this disease process accounts for approximately
235,000 deaths annually.1 In one series, almost one quarter
of the in-hospital PEs occurred in postoperative patients.4
Factors that place patients at increased risk for develop-
ment of PE include hypercoagulability, blood flow stasis,
and endothelial cell damage. It is likely that the latter two
processes underlie the increased risk of DVT and PE in
most surgical patients. Several series have shown venous
stasis and vein lumen dilatation, thought to subsequently
cause endothelial cell damage, during operative proce-
dures.5-7 Coleridge-Smith, Hat, and Scurr7 showed, with
ultrasound scan examination, that venous distension oc-
curred during the conduction of the operative procedure
and not at the induction of anesthesia. Clearly, patients
needing major surgical procedures are at increased risk of
DVT and PE. Pooled data from control arms of DVT
prophylaxis trials estimate the incidence rate of DVT in the
general surgery population to be approximately 25% in
untreated subjects, and this incidence rate rises to 65% in
those undergoing elective orthopedic surgery.8 With the
institution of routine pharmacologic and mechanical DVT
prophylaxis, these rates have been reduced three-fold.9,10
The risk of DVT and PE in the vascular surgery popu-
lation has not been well studied. Recent literature suggests
that the incidence rate of DVT after peripheral vascular
surgery varies widely from 2% to 32%.11-15 With the advent
of endovascular repair of abdominal aortic aneurysms
(AAAs), a subset of patients not previously eligible for open
operative repair may be undergoing operative intervention.
These patients may be at increased risk for the development
of DVT compared with those undergoing conventional
open repair. These more elderly patients with more comor-
bidities are more likely to be sedentary than those under-
going open procedures. The incidence rate of malignant
disease in this population has been reported as high as
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12%.16 Prolonged device manipulation within the femoral
and iliac arteries may result in trauma to the adjacent veins,
injure the endothelium, and incite DVT formation. Despite
these factors, DVT and PE complicating endovascular AAA
repair has been recognized in only 1% to 2% of pa-
tients.16,17 The aim of this study was to evaluate the inci-
dence of acute DVT and risk factors for DVT after endo-
vascular AAA repair.
PATIENTS AND METHODS
Fifty consecutive patients who underwent endovascular
treatment of an AAA between January 2000 and August
2001 at the University of Michigan Hospital were studied
prospectively. Included were 42 men and eight women, rang-
ing in age from 48 to 85 years (mean, 72 1 years). Comor-
bidities included patient demographics, history of cancer,
prior DVT, and history of hypercoagulable states. Intraoper-
ative data, in- cluding graft type, mode of anesthesia, operative
time, estimated blood loss, volume and type of blood product
transfused, dose of heparin, and the dose of protamine admin-
istered were analyzed. Utilization of perioperative anticoagula-
tion therapy was also examined. The University of Michigan
Internal Review Board (#2001-773) approved this study.
In all patients, bilateral lower extremity duplex ultra-
sonography for acute DVT was performed on the first
postoperative day and at the first follow-up visit (within 4
weeks after discharge) according to an established protocol
for endovascular aortic aneurysm repairs. Duplex ultra-
sonography was performed with a high-resolution real-time
imager and integrated, pulsed, range-gated Doppler with
color flow imaging with a 5-MHz to 7.5-MHz transducer.
The posterior tibial, anterior tibial, peroneal, popliteal,
femoral, common femoral, and external iliac veins were as-
sessed. Acute thrombus was considered present when echolu-
cent intravenous material hindering vein wall compression was
noted in conjunction with a dilated vein and lack of well-
formed collaterals. Absence of augmented signals with respi-
ration and a lack of vessel filling with color mode were also
suggestive of acute DVT.18 All examinations were performed
by licensed or registered vascular technologists and re-
viewed by board certified vascular surgeons in an Interso-
cietal Commission for the Accreditation of Vascular Labo-
ratories–accredited laboratory. The University of Michigan
Diagnositc Vascular Unit images entire lower extremity
DVTs with duplex ultrasonography with a sensitivity of
96%, a specificity of 90%, and an accuracy of 95%. For the
diagnosis of calf vein DVT, the sensitivity, specificity,
and accuracy are reduced to 82%, 77%, and 80%, respec-
tively.
Data are expressed as the mean the standard error of
the mean unless otherwise stated. Risk factors for DVT
were evaluated with 2 analysis for nominal data and the
Wilcoxan rank-sum test for continuous data. All statistical
analyses were performed with StatView Version 4.5 (Aba-
cus Concepts, Inc, Berkely, Calif).
RESULTS
None of the 50 patients had a prior DVT or identifiable
hypercoagulable state. However, seven patients (14%) had
concurrent malignant disease that included: metastatic
Merckel cell carcinoma (n 1), esophageal cancer (n 1),
cutaneous basal cell carcinoma (n 1), renal cell carcinoma
(n 1), and prostate cancer (n 3). The characteristics of
the patients in this series were typical of individuals with
AAAs (Table I).
Before surgery, 26 patients (52%) were receiving anti-
platelet agents and nine (18%) were on warfarin sodium
therapy (six for atrial fibrillation, two for severe ventricular
dysfunction, and one for a mechanical heart valve). Anti-
platelet agents were continued perioperatively. Patients
receiving warfarin sodium therapy had this medication dis-
continued 4 days before surgery. They were started on
subcutaneous low-molecular weight heparin after surgery
and were continued on this drug until their international
normalized ratio was above 2.0. No new DVT prophylaxis
was initiated perioperatively to this series’ patients.
Two patients who underwent AAA repair had con-
tained aortic ruptures, and one patient was symptomatic
with back pain but no evidence of rupture on computed
tomographic scan. Eight AAAs were less than 5 cm in diam-
eter. Two of these aneurysms had concurrent 4-cm and 5-cm
iliac artery aneurysms. One of these less than 5-cm aneurysms
presented as a contained rupture, and another was symptom-
atic. Three of these aneurysms had a greater than 0.5-cm
increase in anteroposterior diameter over a period of 6
months. The last patient with a less than 5-cm AAA had a
discrete sacular aneurysm, suggesting an advanced degenera-
tive process affecting a focal area of the aorta.
Operative data were revealing (Table II). Twenty-two
percent of the patients did not receive protamine. One
patient was converted to open repair because of intraoper-
ative rupture of the external iliac artery. Complications
included one patient needing an iliofemoral thrombectomy
in the immediate postoperative period because of a com-
mon femoral artery dissection. One patient had a postop-
erative myocardial infarction and had acute renal failure
Table I. Patient demographics
Age (y) 72  1 (48 to 85)
Gender
Male 42 (84%)
Female 8 (16%)
Medical history
Hypertension 30 (60%)
Coronary artery disease 33 (66%)
Cerebrovascular disease 9 (18%)
Diabetes 3 (6%)
Current smoker 6 (12%)
Previous smoker 27 (54%)
Marfan syndrome 1 (2%)
Previous DVT 0 (0%)
Hypercoaguable state 0 (0%)
Current cancer 7 (14%)
AAA size (cm) 5.9  0.2 (4 to 9.4)
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develop. This patient did not need acute dialysis. Ambula-
tion occurred, on average, on postoperative day 2  0.3
(range, 1 to 9 days; median, 1 day). There were no periop-
erative deaths, and median hospital stay was 2 days (range,
1 to 18 days). Follow-up for all patients averaged 8  0.8
months (range, 1 to 18 months).
Three patients (6%) had an acute DVT develop after
surgery, two affecting the femoral veins and one affecting
the popliteal vein (Table III). All these patients had re-
ceived 5000 units of heparin during surgery, and all under-
went reversal with protamine. In the first patient, an acute
DVT was observed affecting the left popliteal vein with
duplex ultrasonography on the first postoperative day. The
patient was asymptomatic. The second patient had previous
arterial surgery necessitating a femoral artery dissection,
and during the dissection for the endovascular graft device
placement, the femoral vein was injured. This patient had
pain and swelling on the affected side on the first postop-
erative day. A duplex ultrasound scan revealed an acute
DVT in the common femoral vein. The third patient had
initial duplex ultrasonographic examinations that revealed
no evidence of DVT. The individual had metastatic Mer-
ckel cell carcinoma and was begun on chemotherapy, in-
cluding paclitaxel and carboplatin 1 week after surgery. The
patient was seen for follow-up 1 month after aneurysm
repair with unilateral leg swelling and pain. Duplex ultra-
sonography revealed an acute right midfemoral DVT. No
identified factors placed these patients at significantly
greater risk for the development of acute DVT compared to
those without DVT. No patient with DVT had evidence of
PE. Two of the patients had no long-term sequelae from
their DVT or anticoagulation therapy. One patient had
gastrointestinal bleeding develop from gastritis and had the
warfarin sodium therapy discontinued after 4 months of
treatment. There were no mortalities among the 50 pa-
tients studied.
DISCUSSION
The risk of perioperative DVT formation after conven-
tional aortic surgery remains ill defined. Early studies with
125I-labeled fibrinogen with or without a second modality
placed the risk for DVT formation between 1.5% and 40%
after aortic surgery.19-22 The use of labeled fibrinogen,
however, is inaccurate and has been abandoned because it is
poor at detecting proximal thigh and pelvic thrombus and
there was a high incidence rate of false-positives study
results.20 Venography, once the gold standard for DVT
diagnosis, was used in one study to assess the incidence of
DVT formation after aortic surgery, with a reported inci-
dence rate of 18%.12 All of the patients in the latter study
were asymptomatic, and 78% had the DVT limited to a calf
vein. On the basis of the data from the latter study, Olin et
al12 recommended that patients undergoing conventional
aortic surgery may benefit from DVT prophylaxis.
More recently, duplex ultrasonography has been used
to diagnose DVT in several studies of patients undergoing
open aortic surgery. With this method, the reported inci-
dence rate of DVT formation after traditional open AAA
repair still varies widely, ranging from 2% to 41%.13-15,23
Hollyoak et al15 recently studied the incidence of DVT
after major vascular surgical procedures without routine
DVT prophylaxis and reported a 41% incidence rate of
DVT after open aortic surgery. Similar to the report of Olin
et al,12 most of these DVTs (80%) were confined to the calf
veins. Fletcher and Batiste14 documented the incidence
rate of DVT after aortic surgery to be 11.5% despite DVT
prophylaxis with unfractionated heparin. Farkas and col-
leagues,23 however, noted a lessening of DVT from 10.6%
to 4.2% with prophylaxis with low-molecular weight hepa-
rin compared with unfractionated heparin. Killewich et al13
showed no difference in the incidence rate of DVT between
patients receiving DVT prophylaxis with unfractionated
heparin (2%) compared with those not given DVT prophy-
laxis (2%).
This study represents a group of patients undergoing
AAA repair with an endovascular approach. Before this
report, there has been no clear documentation as to the risk
of DVT after endovascular AAA repair. One could argue
that shortened hospital stays and earlier return to daily
activities should reduce the risk of DVT formation. How-
ever, given that most DVTs in surgical patients develop
during the time of the operation, the risk in this group may
not necessarily be lower. Furthermore, one could speculate
that prolonged instrumentation of the femoral vessels may
lead to an increased risk of DVT formation. Although none
of these patients had a history of hypercoaguable state, two
patients were operated on for aortic rupture and a third
patient for suspected rupture. Bradbury and colleagues24
suggest that there is a hypercoaguable state associated with
ruptured aortic aneurysms. Forty percent of the patients in
that series had thrombocytosis develop, and these patients
were at higher risk for development of a DVT. Although
none of the ruptured aneurysms in this series had a DVT
develop, none had postoperative thrombocytosis develop.
Table II. Operative data
Graft type
AneuRx* 32 (64%)
Ancure† 18 (36%)
Anesthesia type
General 20 (40%)
Epidural 30 (60%)
Operative approach
Femoral cutdown 49 (98%)
Iliac conduit 1 (2%)
Operative time (min) 276  16 (75 to 646)
Intraoperative heparin dose
(U)
5793  240 (5000 to 10,000)
Protamine dose (mg) 37  5 (0 to 125)
Blood products
Packed red blood cells (U) 0.5  0.02 (0 to 8)
Platelets (U) 0.1  0.01 (0 to 5)
Fresh frozen plasma (U) 0.5  0.05 (0 to 2)
Autotransfusion (mL) 0
*AneuRx, Inc, Sunnyvale, Calif.
†Guidant Cardiac and Vascular, Menlo Park, Calif.
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It will be interesting, as more ruptured aneurysms are
repaired in an endovascular fashion, to evaluate whether
these patients have physiologic problems develop similar to
those undergoing conventional ruptured AAA repair.
The 6% incidence rate of DVT in this study appears to
be consistent with the incidence rate reported in earlier
studies after conventional AAA repair. Endovascular AAA
repair appears to carry no increased or decreased risk of
DVT. It may be important to note that there were no calf
vein DVTs documented in this group of patients for endo-
vascular treatment. This is contrary to the reported experi-
ence with open aortic surgery, in which upwards to 80% of
diagnosed DVTs were in the calf veins. Olin et al12 used
venography to diagnose DVT, and thus their study likely
had a higher sensitivity and specificity in diagnosing calf
vein DVT compared with this series and may explain some
of the difference. Hollyoak et al,15 however, used duplex
ultrasonagraphy and continued to have a higher incidence
rate of calf vein DVT. The sensitivity and specificity of
duplex ultrasonography in that series was not reported. No
risk factors placed our patients at increased risk for devel-
opment of acute DVT. In fact, it is likely that the one
patient with metastatic Merkel cell carcinoma had a DVT
develop independent of the endovascular AAA repair. The
patient’s initial duplex scan examinations were negative for
DVT on two occasions, and the patient did not present
until 1 months after surgery soon after beginning chemo-
therapy for the neoplasm.
The small number of patients who underwent endovas-
cular AAA repair and the small number in whom DVT
developed in this study limit the statistical power to accu-
rately identify risk factors for DVT. Assuming a comparison
of two equal groups and a baseline event rate of 6%,
approximately 1600 patients would be required to detect a
50% relative reduction and 7200 patients to detect a 25%
relative reduction for a power of 80% with a two-sided  of
0.05. Thus the limitation of studying only 50 patients is
clearly understood.
On the basis of this current review, and on most previ-
ous studies, no firm recommendation can be made with
regard to DVT prophylaxis during aortic surgery, whether
open or endovascular. One could argue that because most
DVTs in surgical patients develop during the operative
procedures25 and because most vascular surgery patients
receive intravenous heparin therapy during the operation,
that they are already afforded DVT prophylaxis. Certainly,
those patients already on anticoagulation therapy should
continue it perioperatively, provided it is not medically
contraindicated, and those patients with recognized risk
factors for the development of DVT (separate from sur-
gery) may benefit from prophylaxis. However, there is no
justification that patients undergoing endovascular AAA
repair require DVT screening or prophylaxis.
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